Single photon emission computed tomography (SPECT) or positron emission computed tomography (PET) imaging agents for neurodegenerative disease have a significant impact on clinical diagnosis and patient care. The examples of Parkinson's Disease (PD) and Alzheimer's Disease (AD) imaging agents described in this paper provide a general view on how imaging agents, ie radioactive drugs, are selected, chemically prepared and applied in humans. Imaging the living human brain can provide unique information on the pathology and progression of neurodegenerative diseases, such as AD and PD. The imaging method will also facilitate preclinical and clinical trials of new drugs offering specific information related to drug binding sites in the brain. In the future, chemists will continue to play important roles in identifying specific targets, synthesizing target-specific probes for screening and ultimately testing them by in vitro and in vivo assays.
1) What are radiopharmaceuticals and why are they needed?
Radiopharmaceuticals, often referred to as radiolabeled diagnostic drugs, radioactive tracers or probes, are injected intravenously into patients for diagnostic purposes in conjunction with single photon emission computed tomography (SPECT) or positron emission computed tomography (PET). 1 Molecular imaging, which enables the visualization of the cellular function and molecular processes in living humans, tissues or organisms, is a discipline at the intersection of molecular biology and in vivo imaging.
Although PET and SPECT imaging are most prevalent, other imaging modalities, such as magnetic resonance imaging (MRI), x-ray computer tomography (CT), ultrasound or optical imaging could also be used for molecular imaging. The contrast agents for MRI, CT and ultrasound imaging are at a higher chemical concentration (µM to mM range) than those used for PET and SPECT (pM to nM). Molecular imaging merges many research disciplines with the potential for integrating diagnosis and drug development, as well as opening up the possibility of individualized molecular medicine. 2 In the foreseeable future, it is likely that neurodegenerative diseases will be diagnosed and monitored with targeted imaging agents used in conjunction with either PET or SPECT scanners. 3 Both SPECT and PET are tomographic imaging techniques.
They use sensitive detectors to collect gamma rays emitted from the injected radioprobes into patients designed to create maps of cellular distribution and function. It is not possible to obtain information about the location and quantity of specific receptors or binding sites in the living human brain by other methods (i.e. magnetic resonance imaging MRI, or computer tomography, CT). 4 
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It is well recognized that PET has higher resolution, higher sensitivity and is better for quantification than SPECT imaging is. On the other hand, there are more hospitals equipped with SPECT scanners. Therefore, it is more practical to design agents for use with SPECT. Readers interested in learning more about the physics and instrumentation of PET and SPECT are encouraged to consult the book by Cherry et al. 5 With the recent development of combined SPECT/CT and PET/CT scanners, clinicians are able to compare three-dimensional anatomical CT images with PET or SPECT scans, which provide information about biochemical function. This is a powerful tool for the evaluation of CNS function in both normal and disease states.
An effective radiopharmaceutical for neurodegenerative diseases has several characteristics: First of all, it is labeled with a short-lived isotope, which provides gamma ray emission. Isotopes, such as 99m Tc which emits medium energy photons (140 KeV), are useful for SPECT imaging; while positron emitting isotopes, such as 18 F, emit a positron, which collides with near by electrons. The resulting annihilation reaction between a positron and an electron produces two 511 KeV photons for PET imaging.
Most of the diagnostic procedures using radiopharmaceuticals are accomplished within a day and a short-lived radioisotope reduces the ionizing radiation dose to patients.
Secondly, it can be injected at very low doses (picogram to nanogram). Therefore, the risk of chemical toxicity is minimal. Thirdly, its distribution in the body is based on specific processes or targeting mechanisms. For example, in brain imaging it means mapping brain function, such as the regional blood perfusion, glucose metabolism or targeting specific neuroreceptors, transporters or other binding sites. 6 This is particularly useful for imaging changes in the receptors and binding sites associated with The only PET imaging agent that has widespread clinical application thus far is 
15, 16
Since it is not always possible to make a final diagnosis based on neurological symptoms, it would be useful for clinicians to be able to monitor the status of monoamine neuron integrity with either PET or SPECT imaging. 16 Imaging agents for
Parkinson's Disease could assist physicians in three critical ways: 1. differential diagnosis of idiopathic vs non-idiopathic PD; 2. early diagnosis of high risk patients (genetic predisposition or environmental exposure to toxin); 3. monitoring drug treatment. and show a high uptake in the brain (> 1.0 %dose/g of striatum at 2 min after an iv injection in rats); 5. display a high selective uptake and retention in the striatum (striatum/cerebellum (= target/non-target) ratio > 3); 6. show high in vivo stability; 7.
have kinetic properties which can be modelled to obtain quantitative information by in vivo imaging. All of these requirements need to be met in order to effectively and quantitatively map the neuronal function in the living human brain.
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Page 12 of 31 Chemical Society Reviews (Fig 5A) . The dopamine inside the neuron is then re-packaged into vesicles by the vesicular monoamine transporter 2 (VMAT2) (Fig. 3) . When the dopamine neurons are functioning normally, there will be plenty of DAT available for binding to the high affinity DAT tracers. A high accumulation of radiolabeled tracers in the basal ganglia and substantia nigra of the brain, as measured by PET or SPECT, suggests that the neurons are intact. However, a reduction in the uptake of a DAT tracer usually suggests a loss of dopamine neurons.
Imaging dopamine transporters (DAT)
Many of the agents for imaging DAT belong to a group of tropane derivatives, which have a backbone structure similar to that of cocaine and compete to the same dopamine transporter binding sites (Fig. 4) . The design criteria for this group of DAT imaging agents are based on their structural similarity to cocaine and high affinity to the DAT binding sites in the brain. In the past two decades, an abundance of DAT imaging agents have been developed, most of which are tropane (or cocaine) derivatives.
Although tropanes show excellent binding affinity to DAT (Ki < 10 nM), many of them also have varying degrees of binding affinity to serotonin and norepinephrine transporters. However, because the total number of DAT binding sites in the basal ganglia and substantia nigra area is much higher than the number of serotonin or norepinephrine transporters, interference from other binding sites is not significant. 
Imaging vesicular monoamine transporter 2 (VMAT2)
Radiolabeled series of patients suggest that DLB and PD patients showed significant reduction of VMAT2 in the basal ganglia region of the brain, while the healthy subject and the AD patient showed no change. These images suggest that this method may be very useful not only for the diagnosis of PD but also for differentiating AD from DLB patients, as both types of patients may exhibit dementia. 28 The DLB patients are often presented as a dementia patient with co-morbidity of PD.
4) In vivo imaging of human amyloid plaques in Alzheimer's disease
Alzheimer's disease (AD) is a neurodegenerative disease affecting millions of people. As our population ages, there will be an increasing number of AD patients.
Clinical symptoms of AD include cognitive decline, irreversible memory loss, disorientation, language impairment, etc. Major neuropathological observations from postmortem AD brains include the presence of plaques (β-amyloid, Aβ) aggregates, and neurofibrillary tangles (hyper phosphorylated Tau) (Fig. 6 ). Familial AD has been reported to have mutations in the genes encoding the β-amyloid precursor proteins (APP), presenilin 1 (PS1) and presenilin 2 (PS2). The exact mechanisms by which these mutations lead to the development of AD are not fully understood. However, there The development of Aβ plaque-specific imaging agents has been extensively reported and reviewed. 32, 33 The most well characterized PET imaging agent for Aβ plaques in the brain is [ Although much has been already accomplished in the field of neuroimaging, there are many targets of neurodegenerative diseases, which remain to be explored.
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For PD imaging, it would be useful to develop an agent to image the presence of α-synuclein in the brain. 44 In Alzheimer's Disease imaging, researchers are already working to develop a probe for the second hallmark of AD, Tau aggregates. 45 Imaging agents for these targets would be extremely useful to compliment the tracers currently being used for diagnosis of AD and PD.
5). Summary
Developing PET/SPECT imaging agents for neurodegenerative disease is a multidisciplinary research field. The examples of PD and AD imaging agents described in this paper suggest that chemists can continue to play important roles in identifying specific targets, synthesizing target-specific tracers for screening and ultimately testing them by in vitro and in vivo assays.
It is important to note that developing a tracer from lab bench to clinical trial and ultimate FDA approval takes a significant amount of resources far above and beyond the scope of a single research project. It is estimated that 50 to 100 million US dollars will be needed to develop one diagnostic compound. Basic research, supported by NIH grants and other government resources, plays a critical role in the initial proof of concept of new drug candidates, which might convince commercial companies to invest major resources, which are needed to obtain final FDA drug registration. 
